Point72 Asia Singapore Pte. Ltd. Makes New $76,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,053 shares of the biopharmaceutical company’s stock, valued at approximately $76,000.

Several other institutional investors also recently modified their holdings of the business. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics during the 1st quarter worth $147,000. CANADA LIFE ASSURANCE Co increased its holdings in shares of Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares during the period. Quest Partners LLC raised its position in shares of Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 6,879 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 638 shares in the last quarter.

Celldex Therapeutics Stock Down 0.6 %

Celldex Therapeutics stock opened at $30.65 on Friday. Celldex Therapeutics, Inc. has a twelve month low of $22.11 and a twelve month high of $53.18. The stock has a market cap of $2.03 billion, a P/E ratio of -10.75 and a beta of 1.55. The company’s 50-day moving average price is $37.45 and its two-hundred day moving average price is $37.93.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The business had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CLDX. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, September 26th. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. Stifel Nicolaus assumed coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target on the stock. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $61.14.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.